184 related articles for article (PubMed ID: 27866808)
1. Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development.
Ishay Y; Zimran A; Szer J; Dinur T; Ilan Y; Arkadir D
Blood Cells Mol Dis; 2018 Feb; 68():117-120. PubMed ID: 27866808
[TBL] [Abstract][Full Text] [Related]
2. Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data.
Istaiti M; Revel-Vilk S; Becker-Cohen M; Dinur T; Ramaswami U; Castillo-Garcia D; Ceron-Rodriguez M; Chan A; Rodic P; Tincheva RS; Al-Hertani W; Lee BH; Yang CF; Kiec-Wilk B; Fiumara A; Rubio B; Zimran A
Am J Hematol; 2021 May; 96(5):545-551. PubMed ID: 33606887
[TBL] [Abstract][Full Text] [Related]
3. The contribution of mutant GBA to the development of Parkinson disease in Drosophila.
Maor G; Cabasso O; Krivoruk O; Rodriguez J; Steller H; Segal D; Horowitz M
Hum Mol Genet; 2016 Jul; 25(13):2712-2727. PubMed ID: 27162249
[TBL] [Abstract][Full Text] [Related]
4. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
McNeill A; Magalhaes J; Shen C; Chau KY; Hughes D; Mehta A; Foltynie T; Cooper JM; Abramov AY; Gegg M; Schapira AH
Brain; 2014 May; 137(Pt 5):1481-95. PubMed ID: 24574503
[TBL] [Abstract][Full Text] [Related]
5. Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism.
Kopytova AE; Rychkov GN; Nikolaev MA; Baydakova GV; Cheblokov AA; Senkevich KA; Bogdanova DA; Bolshakova OI; Miliukhina IV; Bezrukikh VA; Salogub GN; Sarantseva SV; Usenko TC; Zakharova EY; Emelyanov AK; Pchelina SN
Parkinsonism Relat Disord; 2021 Mar; 84():112-121. PubMed ID: 33609962
[TBL] [Abstract][Full Text] [Related]
6. Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase.
Bendikov-Bar I; Maor G; Filocamo M; Horowitz M
Blood Cells Mol Dis; 2013 Feb; 50(2):141-5. PubMed ID: 23158495
[TBL] [Abstract][Full Text] [Related]
7. Study protocol of the GRoningen early-PD Ambroxol treatment (GREAT) trial: a randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA mutation.
Siemeling O; Slingerland S; van der Zee S; van Laar T
BMC Neurol; 2024 May; 24(1):146. PubMed ID: 38693511
[TBL] [Abstract][Full Text] [Related]
8. Potential Binding Sites of Pharmacological Chaperone NCGC00241607 on Mutant β-Glucocerebrosidase and Its Efficacy on Patient-Derived Cell Cultures in Gaucher and Parkinson's Disease.
Kopytova AE; Rychkov GN; Cheblokov AA; Grigor'eva EV; Nikolaev MA; Yarkova ES; Sorogina DA; Ibatullin FM; Baydakova GV; Izyumchenko AD; Bogdanova DA; Boitsov VM; Rybakov AV; Miliukhina IV; Bezrukikh VA; Salogub GN; Zakharova EY; Pchelina SN; Emelyanov AK
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240451
[TBL] [Abstract][Full Text] [Related]
9. Neurological effects of glucocerebrosidase gene mutations.
Mullin S; Hughes D; Mehta A; Schapira AHV
Eur J Neurol; 2019 Mar; 26(3):388-e29. PubMed ID: 30315684
[TBL] [Abstract][Full Text] [Related]
10. New Directions in Gaucher Disease.
Horowitz M; Elstein D; Zimran A; Goker-Alpan O
Hum Mutat; 2016 Nov; 37(11):1121-1136. PubMed ID: 27449603
[TBL] [Abstract][Full Text] [Related]
11. Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Mullin S; Smith L; Lee K; D'Souza G; Woodgate P; Elflein J; Hällqvist J; Toffoli M; Streeter A; Hosking J; Heywood WE; Khengar R; Campbell P; Hehir J; Cable S; Mills K; Zetterberg H; Limousin P; Libri V; Foltynie T; Schapira AHV
JAMA Neurol; 2020 Apr; 77(4):427-434. PubMed ID: 31930374
[TBL] [Abstract][Full Text] [Related]
12. Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models.
Sanchez-Martinez A; Beavan M; Gegg ME; Chau KY; Whitworth AJ; Schapira AH
Sci Rep; 2016 Aug; 6():31380. PubMed ID: 27539639
[TBL] [Abstract][Full Text] [Related]
13. Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice.
Migdalska-Richards A; Daly L; Bezard E; Schapira AH
Ann Neurol; 2016 Nov; 80(5):766-775. PubMed ID: 27859541
[TBL] [Abstract][Full Text] [Related]
14. Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease.
Ivanova MM; Dao J; Kasaci N; Adewale B; Nazari S; Noll L; Fikry J; Sanati AH; Goker-Alpan O
PLoS One; 2021; 16(10):e0247211. PubMed ID: 34695170
[TBL] [Abstract][Full Text] [Related]
15. Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease.
Ron I; Rapaport D; Horowitz M
Hum Mol Genet; 2010 Oct; 19(19):3771-81. PubMed ID: 20643691
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacological chaperone therapy for the treatment of inborn errors of metabolism].
Lipiński P; Jezela-Stanek A; Tylki-Szymańska A
Postepy Biochem; 2022 Sep; 68(3):255-263. PubMed ID: 36317990
[TBL] [Abstract][Full Text] [Related]
17. The additive effect on the antiepileptic treatment of ambroxol in type 3 Gaucher patient. The early observation.
Pawlinski L; Malecki MT; Kiec-Wilk B
Blood Cells Mol Dis; 2018 Feb; 68():192-193. PubMed ID: 28007403
[No Abstract] [Full Text] [Related]
18. Ambroxol Chaperone Therapy for Gaucher Disease Type I-Associated Liver Cirrhosis and Portal Hypertension: A Case Report.
Zhang P; Zheng MF; Cui SY; Zhang W; Gao RP
Endocr Metab Immune Disord Drug Targets; 2022; 22(6):658-662. PubMed ID: 34802413
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease.
Maegawa GH; Tropak MB; Buttner JD; Rigat BA; Fuller M; Pandit D; Tang L; Kornhaber GJ; Hamuro Y; Clarke JT; Mahuran DJ
J Biol Chem; 2009 Aug; 284(35):23502-16. PubMed ID: 19578116
[TBL] [Abstract][Full Text] [Related]
20. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells.
Ambrosi G; Ghezzi C; Zangaglia R; Levandis G; Pacchetti C; Blandini F
Neurobiol Dis; 2015 Oct; 82():235-242. PubMed ID: 26094596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
